12:00 AM
 | 
Apr 20, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CCL2-LPM: Phase Ib started

Osprey began an open-label, dose-escalation, Canadian Phase Ib trial to evaluate intravenous CCL2-LPM in up to 30 patients....

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >